International Assets Investment Management LLC boosted its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 3,287.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 328,772 shares of the company’s stock after buying an additional 319,065 shares during the quarter. International Assets Investment Management LLC’s holdings in Ionis Pharmaceuticals were worth $13,171,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. TD Asset Management Inc increased its position in shares of Ionis Pharmaceuticals by 6.1% during the 2nd quarter. TD Asset Management Inc now owns 952,762 shares of the company’s stock valued at $45,409,000 after purchasing an additional 54,400 shares during the last quarter. Candriam S.C.A. increased its position in shares of Ionis Pharmaceuticals by 4.0% during the 2nd quarter. Candriam S.C.A. now owns 948,266 shares of the company’s stock valued at $45,192,000 after purchasing an additional 36,369 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Ionis Pharmaceuticals by 12.2% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 571,763 shares of the company’s stock valued at $24,786,000 after purchasing an additional 62,230 shares during the last quarter. Great Point Partners LLC purchased a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter valued at about $15,728,000. Finally, Logos Global Management LP purchased a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter valued at about $14,298,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.
Insider Activity
In related news, EVP Richard S. Geary sold 2,430 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $48.00, for a total transaction of $116,640.00. Following the sale, the executive vice president now owns 85,508 shares in the company, valued at approximately $4,104,384. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 2,803 shares of company stock worth $134,402. 2.71% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Get Our Latest Research Report on IONS
Ionis Pharmaceuticals Stock Down 1.1 %
NASDAQ IONS opened at $39.26 on Thursday. The company has a debt-to-equity ratio of 4.67, a quick ratio of 7.51 and a current ratio of 7.61. The company has a market capitalization of $5.73 billion, a P/E ratio of -14.70 and a beta of 0.38. Ionis Pharmaceuticals, Inc. has a one year low of $35.95 and a one year high of $54.44. The stock has a 50 day moving average price of $42.14 and a 200-day moving average price of $43.07.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.47. The firm had revenue of $225.00 million during the quarter, compared to the consensus estimate of $152.35 million. Ionis Pharmaceuticals had a negative return on equity of 115.66% and a negative net margin of 44.90%. The company’s quarterly revenue was up 19.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.60 EPS. As a group, equities analysts predict that Ionis Pharmaceuticals, Inc. will post -3.67 EPS for the current fiscal year.
Ionis Pharmaceuticals Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Featured Articles
- Five stocks we like better than Ionis Pharmaceuticals
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Basic Materials Stocks Investing
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Insider Trades May Not Tell You What You Think
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.